Adenosine has been proposed to promote sleep through A1 receptors (A 1R's) and/or A2A receptors in the brain. We previously reported that A 2A receptors mediate the sleep-promoting effect of prostaglandin D2, an endogenous sleep-inducing substance, and that activation of these receptors induces sleep and blockade of them by caffeine results in wakefulness. On the other hand, A 1R has been suggested to increase sleep by inhibition of the cholinergic region of the basal forebrain. However, the role and target sites of A1R in sleep-wake regulation remained controversial. In this study, immunohistochemistry revealed that A 1R was expressed in histaminergic neurons of the rat tuberomammillary nucleus (TMN). In vivo microdialysis showed that the histamine release in the frontal cortex was decreased by microinjection into the TMN of N 6 -cyclopentyladenosine (CPA), an A1R agonist, adenosine or coformycin, an inhibitor of adenosine deaminase, which catabolizes adenosine to inosine. Bilateral injection of CPA into the rat TMN significantly increased the amount and the delta power density of non-rapid eye movement (non-REM; NREM) sleep but did not affect REM sleep. CPA-promoted sleep was observed in WT mice but not in KO mice for A 1R or histamine H1 receptor, indicating that the NREM sleep promoted by A 1R-specific agonist depended on the histaminergic system. Furthermore, the bilateral injection of adenosine or coformycin into the rat TMN increased NREM sleep, which was completely abolished by coadministration of 1,3-dimethyl-8-cyclopenthylxanthine, a selective A 1R antagonist. These results indicate that endogenous adenosine in the TMN suppresses the histaminergic system via A 1R to promote NREM sleep.
I
n 1954, Feldberg and Sherwood (1) showed that intraventricular injection of micromole quantities of adenosine into cats caused a state resembling natural sleep of 30-min duration. Subsequent pharmacological studies from several laboratories demonstrated that adenosine and its receptor agonists promoted, but antagonists such as caffeine, inhibited both non-rapid eye movement (non-REM; NREM) and REM sleep (for review, see refs. 2, 3). However, the exact molecular mechanisms underlying sleep-wake regulation by adenosine still remained unclear. Since 1983, we have reported that prostaglandin (PG) D 2 is an endogenous sleep-inducing substance in rodents (4) and monkeys (5) . PGD 2 -induced sleep was indistinguishable from natural physiological sleep as judged by several electrophysiological and behavioral criteria (5) . Subsequent studies have shown that PGD 2 is involved in both circadian (6, 7) and homeostatic regulation of sleep (8) . Further studies on the molecular mechanisms of sleep-wake regulation by PGD 2 demonstrated that PGD 2 is produced by the action of lipocalin-type PGD synthase dominantly expressed in the leptomeninges (9) , binds with PGD receptors (DPRs) exclusively localized in the arachnoid membrane of the basal forebrain (BF) (10) , and promotes sleep through adenosine acting at adenosine A 2A receptors (A 2A R's) (11) , followed by activation of sleep-active neurons in the ventrolateral preoptic (VLPO) area (12, 13) . The somnogenic effect of PGD 2 is mimicked by an A 2A R agonist, but not by an adenosine A 1 receptor (A 1 R) one, and is blocked by an A 2A R antagonist (11) . These findings indicate that the PGD 2 -A 2A R system is involved in both circadian and homeostatic sleep regulation (14) .
Among the four subtypes of adenosine receptors, A 1 , A 2A , A 2B , and A 3 (15) , A 1 R and/or A 2A R subtypes have been reported to mediate the sleep-promoting effect of adenosine. Although A 2A R's involvement in the PGD 2 -VLPO system is clearly established, adenosine via A 1 R has been proposed to induce sleep by inhibiting the cholinergic region of the BF (16) . For example, the unilateral infusion of the BF with an A 1 R-selective antagonist increased waking and decreased sleep (17) . Single unit recording of BF neurons in conjunction with in vivo microdialysis of an A 1 R-selective agonist decreased, and an A 1 R antagonist, increased the discharge activity of the neurons in the BF (18) . Moreover, perfusion of A 1 R antisense oligonucleotides into the BF reduced NREM sleep and EEG delta power (19) . However, infusion of an A 1 R agonist into the lateral ventricle of mice did not alter the amounts of NREM and REM sleep (20) . Caffeine, an antagonist for both A 1 R and A 2A R, increased wakefulness in A 1 R KO mice and in WT mice, but not in A 2A R KO mice (21) . Therefore, the role of A 1 R in sleep-wake regulation has remained uncertain.
In the brain parenchyma, adenosine deaminase (ADA), an enzyme which catabolizes adenosine to inosine, is dominantly localized in the tuberomammillary nucleus (TMN) of the posterior hypothalamus (22) and is colocalized with histidine decarboxylase (HDC) (23), the key enzyme for histamine synthesis. Histaminergic neurons project from the TMN to most of the central nervous system and have been shown to promote wakefulness through histamine H 1 receptors (H 1 R's) (3, 24) . However, the functional significance of adenosine and high expression of ADA in the TMN has not been elucidated so far.
In the present study, we found that A 1 R was coexpressed with ADA in rat TMN and that activation of A 1 R or inhibition of ADA in the TMN inhibited histaminergic systems to promote NREM sleep without affecting REM sleep, clearly indicating that adenosine in the TMN promotes NREM sleep via A 1 R's. anti-A 1 R antibodies revealed that A 1 R was predominantly localized in the TMN in the posterior hypothalamus of rats (Fig.  1A) . On the other hand, no positive staining was observed in the TMN with anti-A 2A R antibody (Fig. 1B) or without the addition of primary antibodies (data not shown). Double immunofluorescence staining with antibodies against A 1 R and HDC ( Fig. 1  C-E) , a marker for histaminergic neurons, or ADA ( Fig. 1 F-H) demonstrated that A 1 R was colocalized with HDC or ADA in the TMN. These results indicate that A 1 R was expressed in HDC-positive neurons and in ADA-positive ones in the TMN.
Results

Localization of A1R in
Inhibitory Action of A1R in Histaminergic Systems of the Rat TMN. To monitor the regulation of histaminergic systems by A 1 R or ADA, we determined the histamine release from the frontal cortex (FrCx) after a bolus injection of a selective A 1 R agonist, N 6 -cyclopentyladenosine (CPA), its natural agonist, adenosine, or an ADA inhibitor, coformycin, into the TMN in urethaneanesthetized rats (Fig. 1J) . The CPA administration into the TMN (0.17-1.5 nmol/side) induced a remarkable dosedependent decrease in the histamine release from the FrCx for 2 h after the injection (Fig. 1K) . The adenosine administration (2.7 or 4.5 nmol/side) also induced a significant decrease in the histamine release for 1 h after the injection in a dose-dependent manner (Fig. 1L) , although the inhibition of the histamine release was weaker and shorter than in the case of CPA. The injection of coformycin (1.3 or 4 nmol/side) also decreased the histamine release for 1 h from 1 h after the injection (Fig. 1M) . These results indicate that the stimulation of A 1 R's in the TMN with CPA or adenosine and the inhibition of ADA with coformycin suppressed the activity of histaminergic systems in the TMN to decrease the histamine release in the FrCx. We then examined the sleep-wake profile after a bilateral injection of CPA into the TMN of freely moving rats at 22:00, when such animals spend most of their time in wakefulness. Typical examples of EEG, electromyogram (EMG), and hypnograms from rats given vehicle or CPA at a dose of 1.5 nmol/side are shown in Fig. 2A . The CPA (1.5 nmol/side) injection remarkably increased NREM sleep for 3 h from 22:30 to 01:30, as compared with the case of the vehicle injection.
As shown in Fig. 2B , CPA at 1.5 nmol/side significantly increased the hourly NREM sleep time by 4.6-, 2.1-, 2.5-, and 2.1-fold during the first, second, third, and fourth hour, respectively, after the injection as compared with the vehicle injection. Enhancement of NREM sleep by the CPA injection concomitantly decreased wakefulness, but did not affect REM sleep. No additional disruption of sleep architecture was observed during the subsequent period. Similar time course profiles were observed with the high (4.5 nmol/side) and middle (0.5 nmol/side) doses of CPA. When CPA at a dose of 0.17 nmol/side was administered, no significant change was found in the sleep-wake profile.
The dose-dependency of NREM sleep promotion by the CPA administration is summarized in Fig. 2C . When the vehicle solution or CPA at 0.17 nmol/side was administered into the TMN, no difference was found in the sleep-wake cycle as compared with the vehicle injection. CPA given at 0.5 and 1.5 nmol/side significantly increased the total amount of NREM sleep during 4 h after the injection by 2.1-and 3.1-fold in comparison with the vehicle injection, whereas REM sleep was not affected. When CPA at 4.5 nmol/side was administered, NREM sleep during 4 h after the injection was increased by 3.0-fold without affecting REM sleep, similar to the case of the 1.5 nmol/side, suggesting that these doses of CPA almost completely activated A 1 R's in the TMN.
When we determined the NREM sleep bout distribution for 4 h after the CPA injection (Fig. 2D) , the CPA treatments (0.5-4.5 nmol/side) decreased the number of the shorter NREM sleep bouts (60-120 sec) and increased the number of the prolonged ones (Ͼ240 sec) in a dose-dependent manner as compared with the vehicle injection. On the other hand, the CPA administration did not affect the numbers of stage transition from NREM sleep to wakefulness, wakefulness to NREM sleep, NREM to REM sleep, and REM sleep to wakefulness. These results suggest that CPA did not increase the total number of NREM sleep bouts but extended the duration of NREM sleep.
Also, CPA administration into the TMN increased the delta power density of NREM sleep (Fig. 2E) . CPA at 1.5 or 4.5 nmol/side significantly increased the peak of the power density curve in the delta range of 0.5-4.0 Hz as compared with the vehicle. The low dose of CPA (0.17 or 0.5 nmol/side) showed a tendency to increase the power density curve of the delta range, although the difference was not statistically significant. These results clearly indicate that activation of A 1 R in the dosedependent TMN increased the amount and the delta power density of NREM sleep.
NREM Sleep Promotion by Activation of A1R in the TMN of WT but not KO Mice for A1R or H1R.
To investigate the specificity of CPA against A 1 R in vivo, we bilaterally injected CPA into the TMN of WT and A 1 R KO mice of the same littermates (Fig. 3A) . CPA at 0.3 nmol/side increased NREM sleep in the WT mice by 1.8-, 3.4-, 1.7-, and 2.4-fold during the first, second, third, and fourth hour, respectively, after the injection as compared with that of the baseline day. However, A 1 R KO mice did not display any significant changes in NREM sleep after the CPA administration. The total amount of NREM sleep for 4 h after administration of CPA at 0.3 nmol/side increased by 2.1-fold in the WT mice from the baseline, whereas no difference was observed in the A 1 R KO mice (Fig. 3B ), indicating that A 1 R is crucial for the increased NREM sleep by CPA injected into the TMN. When CPA (0.3 nmol/side) was administered to the TMN of WT and histamine H 1 R KO mice, the NREM sleep was significantly increased in WT mice by 2.9-, 4.9-, and 2.4-fold during the first, second, and fourth hour, respectively, after the injection (Fig.  3C) , giving a 2.8-fold increase during 4 h after the injection (Fig.  3D ) from the baseline, but not in the H 1 R KO mice at all. However, REM sleep was not affected by the treatment of CPA in WT, A 1 R KO, or H 1 R KO mice. These results clearly indicate that the increased NREM sleep by activation of A 1 R's in the TMN depended on the H 1 R-related arousal system.
NREM Sleep Promotion by Administration of Adenosine or ADA
Inhibitor, Coformycin, to the Rat TMN. We then examined the effects of the bilateral injection of adenosine or coformycin into the TMN on the sleep-wake profile of rats. The time courses of NREM and REM sleep after administration of adenosine and coformycin are shown in Fig. 4A and B, respectively. Adenosine at 4.5 nmol/side significantly increased the hourly NREM sleep time by 2.2-, 2.6-, and 1.8-fold during the first, second, and third hour, respectively, as compared with the vehicle injection. Coformycin at 4 nmol/side also induced a significant increase in NREM sleep, by 2.0-and 1.8-fold during the third and fourth hour, respectively, with a lag time of ϳ2 h after the injection, similar to the pattern of decrease in the histamine release. Enhancement of NREM sleep by the injection of adenosine or coformycin concomitantly decreased wakefulness, but neither affected the amount of REM sleep nor disrupted additional sleep architecture during the subsequent period. Similar time course profiles were observed with the middle dose (2.7 nmol/ side) of adenosine or the low (1.3 nmol/side) and high (12 nmol/side) doses of coformycin. No significant change was found in the sleep-wake profile at a low dose of adenosine (1.5 nmol/side).
The dose-dependency of NREM sleep promotion during 4 h after the administration of adenosine or coformycin is summarized in Fig. 4C . As compared with the vehicle injection, adenosine did not alter the total amount of NREM sleep at a dose of 1.5 nmol/side but increased the amount of NREM sleep by 1.5-and 1.8-fold at doses of 2.7 and 4.5 nmol/side, respectively, in a dose-dependent manner. On the other hand, coformycin increased the total amount of NREM sleep weakly at a dose of 1.3 nmol/side and 1.9-and 1.7-fold at 4 and 12 nmol/side, respectively, suggesting that the latter two doses of coformycin almost completely inhibited ADA in the TMN. However, the treatment with adenosine (1.5-4.5 nmol/side) or coformycin (1.3-12 nmol/side) did not change the amount of REM sleep. These results suggest that NREM sleep was promoted by the increased adenosine level in the TMN after the adenosine administration or the inhibition of ADA with coformycin.
Abolishment of Increased NREM Sleep by Adenosine or ADA Inhibitor
with an A1R Antagonist. The increase in NREM sleep by administration of adenosine (4.5 nmol/side) or coformycin (4 nmol/ side) into the rat TMN was completely suppressed by the coadministration of it with 1,3-dimethyl-8-cyclopenthylxanthine (CPT; 0.2 nmol/side), a selective A 1 R antagonist (Fig. 4C) . On the other hand, the injection of CPT per se at the same dose did not produce significant changes in NREM sleep. These results suggest that the NREM sleep, increased by the elevated adenosine level in the TMN, depended on A 1 R's. Moreover, CPT at 0.4 nmol/side significantly decreased NREM sleep by 26% as compared with the vehicle injection, suggesting that A 1 R in the TMN is also involved in physiological sleep. Because of the poor solubility of CPT, we could not examine its effect on the sleep profile at concentrations Ͼ0.4 nmol/side. We did not find significant changes in the REM sleep by the CPT treatment. These results, all together, indicate that the increased adenosine level by adenosine injection or by inhibition of ADA in the TMN promoted the NREM sleep via A 1 R's.
Discussion
In this study, we demonstrated that administration of exogenous adenosine or inhibition of ADA in the TMN suppressed the histaminergic arousal system and increased the amount of NREM sleep. This effect was mimicked by activation of A 1 R with its agonist CPA and abolished with the antagonist CPT. These findings clearly indicate that A 1 R mediates the inhibition of the TMN by adenosine to promote NREM sleep. MurilloRodriguez et al. (26) reported that an A 1 R agonist increased sleep after perfusion into the BF, and Strecker et al. (17) found that the unilateral infusion of an A 1 R-selective antagonist into the BF decreased sleep. We also confirmed that microinjected CPA at 1.5 nmol/side into the BF increased sleep to a lower extent than that given into the TMN (data not shown). In contrast, Methippara et al. (27) reported that administration of an A 1 R agonist into the lateral preoptic area induced wakefulness. These findings indicated that the somnogenic or arousal effect via A 1 R is a region-dependent one and are in good agreement with our previous finding that sleep amounts were not changed at all when an A 1 R agonist was infused into the lateral ventricle of mice (20) .
Our study showed that adenosine is an endogenous suppressor of the histaminergic arousal system. Sherin et al. (28) previously reported the GABAergic and galaninergic innervations of histaminergic TMN neurons from the sleep-active VLPO neurons. We previously identified GABA release in the TMN to inhibit the histaminergic system (29) . Synaptic co-release of ATP and GABA has already been demonstrated (30, 31) . Therefore, ATP co-released with GABA from the VLPO neurons may be a source of adenosine acting as a suppressor in the TMN. On the other hand, we previously reported that the extracellular level of adenosine was increased in the subarachnoid space under the rostral BF after stimulation of DPRs on the arachnoid membrane with PGD 2 (10). The highest DPR immunoreactivity was found in the arachnoid membrane at the basal aspect of the TMN (10). Thus, the adenosine increased by stimulation of DPR in the arachnoid membrane near the TMN may also suppress the histaminergic system.
ADA is dominantly localized in the TMN in the brain parenchyma (22) and has been used as a convenient immunohistochemical marker of histaminergic neurons. However, the physiological function of ADA has not yet been elucidated. Our study clearly showed that ADA in the TMN is involved in the sleep-wake regulation, because treatment of the TMN with the ADA inhibitor coformycin decreased the histamine release in the FrCx and increased NREM sleep. These findings also suggest that endogenous adenosine suppressed the TMN to maintain the NREM sleep pressure under the physiological condition. ADA may decompose local adenosine in the TMN to avoid excessive suppression of the TMN by adenosine.
We found that the A 1 R-mediated suppression of the histaminergic system increased both the duration (Fig. 2D) and the delta-power density (0.5-4 Hz) of NREM sleep (Fig. 2E) . Similar effects were reported by Retey et al. (32) , who found that humans with a genetic variant of ADA, which is associated with the reduced metabolism of adenosine to inosine, exhibited enhanced deep sleep and slow-wave activity (power within Ϸ0.5-5 Hz) during sleep. These observations suggest that the regulation of the histaminergic system by adenosine may be involved in the duration and slow-wave activity of NREM sleep.
We found that the A 1 R-mediated suppression of the histaminergic system extended NREM sleep duration without affecting the total number of NREM sleep bouts in rats (Fig. 2D) , suggesting that the histaminergic systems were involved in the termination of NREM sleep by inducing wakefulness. This interpretation is consistent with our previous finding that H 1 R KO mice showed prolonged duration of NREM sleep episodes as compared with WT mice (33) . In contrast, Takahashi et al. (34) proposed that histaminergic neurons play an important role in the maintenance of the vigilance but not in the induction of wakefulness per se, because they found that these neurons exhibit a pronounced delay in firing during transitions from sleep to wakefulness, as judged from the extracellular single-unit recordings for the histaminergic tuberomammillary neurons in mice. Thus, further analyses are expected to reveal the contribution of the histaminergic system to the switching from NREM sleep to wakefulness.
Direct activation of A 1 R's or inhibition of ADA in the TMN increased NREM sleep but not REM sleep, suggesting that the histaminergic system is closely related to the regulation of NREM sleep and wakefulness and consistent with the evidence that H 1 R KO mice show a decreased number of transition states between wakefulness and NREM sleep but not REM sleep (33) . Alternatively, we previously showed that a PGD 2 or A 2A R agonist suppresses the histaminergic system (12, 13, 29) and increases both NREM and REM sleep (4, 11) . For example, an A 2A R agonist (2 pmol/min) increased slow-wave sleep (NREM sleep) by 71% and paradoxical sleep (REM sleep) by 96% in rats (11) , whereas an A 1 R one at 1.5 nmol/side increased NREM sleep by 3.1-fold but did not change the amount of REM sleep at all (Fig. 2C) . The fact that a PGD 2 or A 2A R agonist activates sleep-active neurons in the VLPO (12, 13) , which innervates histaminergic neurons in the TMN and other monoaminergic arousal nuclei, such as serotonergic neurons in the dorsal raphe nucleus and noradrenergic neurons in the locus ceruleus (28) , suggests that inhibition of these arousal neurons may be involved in the increase in both NREM and REM sleep. These findings suggest that the histaminergic system relatively selectively regulates the transition between wakefulness and NREM sleep.
In conclusion, the activation of A 1 R's expressed in the TMN led to inhibition of the histaminergic system and promotion of NREM sleep.
Materials and Methods
Animals and Chemicals. Male Sprague-Dawley rats, weighing 280 -320 g (8 -10 weeks old), were purchased from Japan SLC Inc. A1R KO mice (35) and H1R KO mice (36) by T. Watanabe, RIKEN Institute, were maintained at Oriental Bioservice, Japan. Both male KO mice and their respective WT littermates of inbred C57BL/6 strain, weighing 20 -26 g (10 -12 weeks old), were used in these experiments. They were housed at an ambient temperature of 22 Ϯ 0.5°C with a relative humidity of 60 Ϯ 2% on an automatically controlled 12:12 h light/dark cycle (light on at 08:00, illumination intensity Ϸ100 lux). They had ad libitum access to food and water. The experimental protocols were approved by the Animal Care Committee of Osaka Bioscience Institute.
Coformycin (Calbiochem), CPA, CPT, and adenosine (Sigma) were dissolved in artificial cerebrospinal fluid (composition: 140 mM NaCl, 3 mM KCl, 1 mM MgCl 2, 1.3 mM CaCl2, 2 mM Na2HPO4, 0.2 mM NaH2PO4, and 4.5 mM glucose; pH 7.4). Aliquots were prepared and frozen at Ϫ20°C and thawed immediately before each experiment.
EEG and EMG Recordings. Under pentobarbital anesthesia (50 mg/kg, i.p.), rats or mice were chronically implanted with EEG and EMG electrodes for polysomnographic recordings (29, 33) and two guide cannulae (outer diameter, 0.55 mm) for drug application. The two guide cannulae were inserted stereotaxically at positions of anteroposterior (AP) Ϫ4.52 mm; left-right (LR) Ϫ0.8 mm; dorsoventral (DV) Ϫ6.2 mm from bregma; 3 mm above the TMN for rats as shown in Fig. 1J or AP Ϫ2.46 mm; LR Ϫ1.0 mm; DV Ϫ3.5 mm from bregma; 2 mm above the TMN for mice according to the atlases (37, 38) . The EEG electrodes, both cannulae, and two stainless steel screws for anchorage were fixed to the skull with dental cement. Two stainless steel wires were placed into neck muscles as EMG electrodes. After 10 days for recovery, each animal was connected to an EEG/EMG recording cable in a soundproof recording chamber and habituated for 3 days before polygraphic recording. The EEG/ EMG signals were amplified, filtered (EEG, 0.5-30 Hz; EMG, 20 -200 Hz), digitized at a sampling rate of 128 Hz, and recorded by using SLEEPSIGN software ver. 3 (Kissei Comtec, Japan) (39).
Pharmacological Treatment. Baseline recordings were taken for 24 h from 20:00. At 22:00 on the next day, CPA, adenosine, coformycin, CPT, or vehicle solution (0.4 l) was injected bilaterally through the cannula (outer diameter, 0.25 mm) inserted into the TMN. To verify correct placement of injection sites, we performed immunohistochemical staining for HDC after EEG/EMG recordings, which staining indicated that the injection cannula reached the TMN (Fig. 1I) .
Vigilance State Analysis. The vigilance states were classified off-line in 10-sec epochs into REM sleep, NREM sleep, and wakefulness by SLEEPSIGN automatically, according to the standard criteria (21) . As a final step, defined sleepwake stages were examined visually and corrected if necessary.
In Vivo Microdialysis Procedure for Measurement of Histamine Release. Under urethane anesthesia (1.2 g/kg, i.p.), rats were implanted with a microdialysis probe (outer diameter, 0.22 mm; Eicom) into the FrCx (AP ϩ 3.2 mm; LR Ϫ1.0 mm; DV Ϫ3.5 mm; membrane length, 2 mm) for monitoring extracellular histamine; and two stainless steel cannulae were introduced into the TMN for administration of CPA, adenosine, or coformycin, as described above. The microdialysis probe was perfused with artificial cerebrospinal fluid at a flow rate of 2 l/min. Two hours after insertion of the microdialysis probe, dialysates were continuously collected from the FrCx at 20-min intervals (40 l each) from 1 h before injection of the drug to the TMN through the cannula to 4 h after the injection. The dialysates were kept at Ϫ20°C until the histamine assay could be performed by HPLC fluorometry (33) .
Immunostaining for Detection of Adenosine Receptors in the Rat TMN. Under deep pentobarbital (50 mg/kg, i.p.) anesthesia, rats were perfused via the heart with PBS followed by 10% formalin solution. The brains were removed and immersed in the same fixative overnight at 4°C, embedded into paraffin, and cut into 10-m sections with a microtome. The sections were incubated with rabbit anti-A1R antibody (1:100; Sigma), raised against amino acid 309-326 of the rat A1R; mouse anti-A1R antibody (1:100) (25) provided by T. Ochiishi, National Institute of Advanced Industrial Science and Technology, Japan; mouse anti-A2AR antibody (1:1000; Upstate); or guinea pig anti-HDC antibody (1:5000; Euro-Diagnostica). They were then incubated with biotinylated anti-rabbit IgG antibody (1:400; Vector), anti-mouse IgG antibody (1:400; Vector) or anti-guinea pig IgG antibody (1:400; Vector), followed by horseradish peroxidase-conjugated avidin (Vectastain kit; Vector). These immunoreactivities were visualized by incubation with 3,3Ј-diaminobenzidine.
